Olysio

RSS

Withdrawn

This medicine's authorisation has been withdrawn

simeprevir
MedicineHumanWithdrawn

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 1 May 2018, the European Commission withdrew the marketing authorisation for Olysio (simeprevir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Janssen-Cilag International NV, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Olysio was granted marketing authorisation in the EU on 14 May 2014 for the treatment of chronic hepatitis C (CHC) in adult patients, in combination with other medicinal products. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for Olysio is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (631.17 KB - PDF)

Vaata

español (ES) (545.76 KB - PDF)

Vaata

čeština (CS) (612.79 KB - PDF)

Vaata

dansk (DA) (544.06 KB - PDF)

Vaata

Deutsch (DE) (549.52 KB - PDF)

Vaata

eesti (ET) (542.55 KB - PDF)

Vaata

ελληνικά (EL) (636.55 KB - PDF)

Vaata

français (FR) (547.32 KB - PDF)

Vaata

hrvatski (HR) (566.73 KB - PDF)

Vaata

italiano (IT) (545.35 KB - PDF)

Vaata

latviešu (LV) (612.55 KB - PDF)

Vaata

lietuvių (LT) (573.19 KB - PDF)

Vaata

magyar (HU) (607.91 KB - PDF)

Vaata

Malti (MT) (615.5 KB - PDF)

Vaata

Nederlands (NL) (545.49 KB - PDF)

Vaata

polski (PL) (612.66 KB - PDF)

Vaata

português (PT) (545.33 KB - PDF)

Vaata

română (RO) (572.83 KB - PDF)

Vaata

slovenčina (SK) (612.97 KB - PDF)

Vaata

slovenščina (SL) (604.67 KB - PDF)

Vaata

suomi (FI) (543.74 KB - PDF)

Vaata

svenska (SV) (544.08 KB - PDF)

Vaata

Product information

български (BG) (2.23 MB - PDF)

Vaata

español (ES) (1.18 MB - PDF)

Vaata

čeština (CS) (1.84 MB - PDF)

Vaata

dansk (DA) (1.19 MB - PDF)

Vaata

Deutsch (DE) (1.22 MB - PDF)

Vaata

eesti (ET) (1.12 MB - PDF)

Vaata

ελληνικά (EL) (2.33 MB - PDF)

Vaata

français (FR) (1.14 MB - PDF)

Vaata

hrvatski (HR) (1.22 MB - PDF)

Vaata

italiano (IT) (1.12 MB - PDF)

Vaata

latviešu (LV) (1.78 MB - PDF)

Vaata

lietuvių (LT) (1.19 MB - PDF)

Vaata

magyar (HU) (1.85 MB - PDF)

Vaata

Malti (MT) (1.97 MB - PDF)

Vaata

Nederlands (NL) (1.21 MB - PDF)

Vaata

polski (PL) (1.9 MB - PDF)

Vaata

português (PT) (1.2 MB - PDF)

Vaata

română (RO) (1.23 MB - PDF)

Vaata

slovenčina (SK) (1.87 MB - PDF)

Vaata

slovenščina (SL) (1.86 MB - PDF)

Vaata

suomi (FI) (1.09 MB - PDF)

Vaata

svenska (SV) (1.16 MB - PDF)

Vaata

Íslenska (IS) (1.17 MB - PDF)

Vaata

norsk (NO) (1.2 MB - PDF)

Vaata
Latest procedure affecting product information:PSUSA/00010255/201705
08/02/2018
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (494.22 KB - PDF)

Vaata

español (ES) (472.79 KB - PDF)

Vaata

čeština (CS) (486.06 KB - PDF)

Vaata

dansk (DA) (473.7 KB - PDF)

Vaata

Deutsch (DE) (473.71 KB - PDF)

Vaata

eesti (ET) (473.48 KB - PDF)

Vaata

ελληνικά (EL) (493.72 KB - PDF)

Vaata

français (FR) (473.61 KB - PDF)

Vaata

hrvatski (HR) (473.63 KB - PDF)

Vaata

italiano (IT) (474.2 KB - PDF)

Vaata

latviešu (LV) (487.42 KB - PDF)

Vaata

lietuvių (LT) (474.24 KB - PDF)

Vaata

magyar (HU) (487.25 KB - PDF)

Vaata

Malti (MT) (486.95 KB - PDF)

Vaata

Nederlands (NL) (472.89 KB - PDF)

Vaata

polski (PL) (486.5 KB - PDF)

Vaata

português (PT) (473.15 KB - PDF)

Vaata

română (RO) (472.56 KB - PDF)

Vaata

slovenčina (SK) (486.79 KB - PDF)

Vaata

slovenščina (SL) (485.7 KB - PDF)

Vaata

suomi (FI) (472.83 KB - PDF)

Vaata

svenska (SV) (472.91 KB - PDF)

Vaata

Íslenska (IS) (472.72 KB - PDF)

Vaata

norsk (NO) (472.92 KB - PDF)

Vaata

Product details

Name of medicine
Olysio
Active substance
simeprevir
International non-proprietary name (INN) or common name
simeprevir
Therapeutic area (MeSH)
Hepatitis C, Chronic
Anatomical therapeutic chemical (ATC) code
J05AE14

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.

For hepatitis C virus (HCV) genotype specific activity.

Authorisation details

EMA product number
EMEA/H/C/002777
Marketing authorisation holder
Janssen-Cilag International NV

Turnhoutseweg 30
B-2340 Beerse
Belgium

Opinion adopted
20/03/2014
Marketing authorisation issued
14/05/2014
Withdrawal of marketing authorisation
01/05/2018
Revision
13

Assessment history

български (BG) (687.46 KB - PDF)

Vaata

español (ES) (530.79 KB - PDF)

Vaata

čeština (CS) (87.91 KB - PDF)

Vaata

dansk (DA) (532.07 KB - PDF)

Vaata

Deutsch (DE) (542.71 KB - PDF)

Vaata

eesti (ET) (528.43 KB - PDF)

Vaata

ελληνικά (EL) (698.83 KB - PDF)

Vaata

français (FR) (530.89 KB - PDF)

Vaata

hrvatski (HR) (572.64 KB - PDF)

Vaata

italiano (IT) (538.07 KB - PDF)

Vaata

latviešu (LV) (664.34 KB - PDF)

Vaata

lietuvių (LT) (575.28 KB - PDF)

Vaata

magyar (HU) (616.82 KB - PDF)

Vaata

Malti (MT) (649.44 KB - PDF)

Vaata

Nederlands (NL) (537.08 KB - PDF)

Vaata

polski (PL) (648.48 KB - PDF)

Vaata

português (PT) (538.2 KB - PDF)

Vaata

română (RO) (576.84 KB - PDF)

Vaata

slovenčina (SK) (631.52 KB - PDF)

Vaata

slovenščina (SL) (650.63 KB - PDF)

Vaata

suomi (FI) (528.94 KB - PDF)

Vaata

svenska (SV) (536.57 KB - PDF)

Vaata

This page was last updated on

Share this page